Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 12/20 | 0.69 |
| ▸ | JAK2 | O60674 | 14/20 | 0.66 |
| ▸ | TYK2 | P29597 | 4/20 | 0.61 |
| ▸ | IKBKB | O14920 | 1/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | SYK | P43405 | 1/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.61 |
| ▸ | JAK3 | P52333 | 1/20 | 0.61 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7966910 | 0.85 | JAK1 (0.70) | JAK1JAK2TYK2IKBKBRIPK2 | |
| SCHEMBL30927824 | 0.84 | JAK1 (0.69) | JAK1JAK2TYK2IKBKBRIPK2 | |
| SCHEMBL11916700 | 0.84 | JAK1 (0.69) | JAK1JAK2TYK2IKBKBRIPK2 | |
| SCHEMBL2238602 | 0.84 | JAK2 (0.80) | JAK1JAK2TYK2IKBKBRIPK2 | |
| SCHEMBL22971017 | 0.83 | JAK1 (0.56) | JAK1JAK2TYK2IKBKBRIPK2 | |
| SCHEMBL22971460 | 0.83 | JAK1 (0.56) | JAK1JAK2TYK2IKBKBRIPK2 | |
| SCHEMBL22971276 | 0.83 | JAK1 (0.56) | JAK1JAK2TYK2IKBKBRIPK2 | |
| SCHEMBL2238798 | 0.82 | JAK1 (0.66) | JAK1JAK2TYK2IKBKBRIPK2 | |
| SCHEMBL11916701 | 0.82 | JAK1 (1.00) | JAK1JAK2TYK2IKBKBRIPK2 | |
| SCHEMBL25310876 | 0.81 | JAK1 (0.48) | JAK1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964616-A | Synthesis method and application of JAK inhibitor drug compound | 珠海联邦制药股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-117924272-A | Synthesis method and application of JAK inhibitor drug intermediate | 珠海联邦制药股份有限公司 | 2024-04-26 | — | — | CN | claimed |
| US-12558360-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | ALFASIGMA S.P.A. (IT) | 2026-02-24 | — | — | US | disclosed |
| US-12486266-B2 | Crystalline form of JAK inhibitor and application thereof | ZHUHAI UNITED LABORATORIES CO., LTD. (CN) | 2025-12-02 | — | — | US | disclosed |
| US-20250289816-A1 | SALTS AND PHARMACUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ALFASIGMA S.P.A. (IT) | 2025-09-18 | — | — | US | disclosed |
| EP-4108664-B1 | CRYSTALLINE FORM OF JAK INHIBITOR AND APPLICATION THEREOF | ZHUHAI UNITED LABORATORIES CO LTD (CN) | 2025-07-09 | — | — | EP | disclosed |
| US-12234235-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | ALFASIGMA S.P.A. (IT) | 2025-02-25 | — | — | US | disclosed |
| CN-119462650-A | Non-goetide method for synthesizing nylon | 沈阳药科大学 | 2025-02-18 | — | — | CN | disclosed |
| US-20240368161-A1 | CYCLOPROPANECARBOXAMIDE-CONTAINING COMPOUNDS AND APPLICATION THEREOF | CGENETECH (SUZHOU,CHINA) CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4446322-A1 | CYCLOPROPANAMIDE-CONTAINING COMPOUND AND USE THEREOF | CGeneTech (Suzhou, China) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| US-20240325405-A1 | COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2024-10-03 | — | — | US | disclosed |
| WO-2010149769-A1 | 5-PHENYL-[1,2,4 ]TRIAZOLO[1,5-A]PYRIDIN-2-YL CARBOXAMIDES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-12-29 | — | — | WO | disclosed |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100029709-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029709-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010187-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010191-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES. | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009047514-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325405-A1 | COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, BMP6, JAK1 | JAK1 3/4885JAK2 5/4885TYK2 79/4885 |
| US-12558360-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | JAK1, IL6, STAT3 | JAK1 1/4885JAK2 8/4885TYK2 62/4885 |
| US-20100029709-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TRAF6, IL6, TLR6 | JAK1 83/4885JAK2 154/4885TYK2 127/4885 |
| US-20240368161-A1 | CYCLOPROPANECARBOXAMIDE-CONTAINING COMPOUNDS AND APPLICATION THEREOF | MCL1, BCL9, BCL9L | JAK1 2434/4885JAK2 516/4885TYK2 2394/4885 |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | JAK1 14/4885JAK2 16/4885TYK2 30/4885 |
| US-12234235-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL6, JAK1, COL1A1 | JAK1 2/4885JAK2 28/4885TYK2 1271/4885 |
| US-12486266-B2 | Crystalline form of JAK inhibitor and application thereof | JAK1, JAK3, JAK2 | JAK1 1/4885JAK2 3/4885TYK2 4/4885 |
| US-20250289816-A1 | SALTS AND PHARMACUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL6, JAK1, BMP6 | JAK1 2/4885JAK2 23/4885TYK2 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.